Alex Thompson
Stock Analyst at Stifel
(4.69)
# 172
Out of 5,240 analysts
42
Total ratings
66.67%
Success rate
29.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Maintains: Buy | $92 → $107 | $75.65 | +41.44% | 4 | May 6, 2026 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $47 → $72 | $63.90 | +12.68% | 2 | Mar 13, 2026 | |
| ANAB AnaptysBio | Maintains: Buy | $56 → $85 | $62.19 | +36.68% | 3 | Mar 5, 2026 | |
| CLDX Celldex Therapeutics | Reiterates: Buy | $58 → $68 | $32.45 | +109.55% | 1 | Feb 26, 2026 | |
| ALMS Alumis | Initiates: Buy | $44 | $24.63 | +78.64% | 1 | Feb 25, 2026 | |
| PALI Palisade Bio | Initiates: Buy | $5 | $1.81 | +176.24% | 1 | Feb 25, 2026 | |
| ASND Ascendis Pharma | Maintains: Buy | $254 → $256 | $245.49 | +4.28% | 4 | Dec 11, 2025 | |
| ARGX argenx SE | Maintains: Buy | $1,028 → $1,248 | $822.13 | +51.80% | 5 | Dec 11, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $52 → $65 | $85.34 | -23.83% | 2 | Sep 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Hold | $20 → $25 | $44.10 | -43.31% | 4 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $16.15 | +36.22% | 1 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $55 | $84.50 | -34.91% | 1 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $19.01 | +89.37% | 1 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $38.31 | +56.62% | 1 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $18.39 | +275.20% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $4.80 | -79.17% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $17.43 | +129.49% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $28.96 | +17.40% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.17 | +2,732.62% | 1 | Dec 14, 2022 |
Spyre Therapeutics
May 6, 2026
Maintains: Buy
Price Target: $92 → $107
Current: $75.65
Upside: +41.44%
Oruka Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $47 → $72
Current: $63.90
Upside: +12.68%
AnaptysBio
Mar 5, 2026
Maintains: Buy
Price Target: $56 → $85
Current: $62.19
Upside: +36.68%
Celldex Therapeutics
Feb 26, 2026
Reiterates: Buy
Price Target: $58 → $68
Current: $32.45
Upside: +109.55%
Alumis
Feb 25, 2026
Initiates: Buy
Price Target: $44
Current: $24.63
Upside: +78.64%
Palisade Bio
Feb 25, 2026
Initiates: Buy
Price Target: $5
Current: $1.81
Upside: +176.24%
Ascendis Pharma
Dec 11, 2025
Maintains: Buy
Price Target: $254 → $256
Current: $245.49
Upside: +4.28%
argenx SE
Dec 11, 2025
Maintains: Buy
Price Target: $1,028 → $1,248
Current: $822.13
Upside: +51.80%
Dianthus Therapeutics
Sep 12, 2025
Maintains: Buy
Price Target: $52 → $65
Current: $85.34
Upside: -23.83%
Travere Therapeutics
Sep 12, 2025
Maintains: Hold
Price Target: $20 → $25
Current: $44.10
Upside: -43.31%
Jun 11, 2025
Reinstates: Buy
Price Target: $22
Current: $16.15
Upside: +36.22%
May 20, 2025
Reinstates: Buy
Price Target: $55
Current: $84.50
Upside: -34.91%
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $19.01
Upside: +89.37%
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $38.31
Upside: +56.62%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $18.39
Upside: +275.20%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $4.80
Upside: -79.17%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $17.43
Upside: +129.49%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $28.96
Upside: +17.40%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.17
Upside: +2,732.62%